KeyBank National Association’s Ligand Pharmaceuticals LGND Stock Holding History

KeyBank National Association’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$648K	Buy	2,049 +175	+9%	+$41.2K	﹤0.01%	803
2026 Q1	$374K	Buy	1,874 +397	+27%	+$78.5K	﹤0.01%	944
2025 Q4	$279K	Buy	1,477 +148	+11%	+$28.4K	﹤0.01%	1047
2025 Q3	$235K	Buy	+1,329	New	+$198K	﹤0.01%	1087
2019 Q3	–	Sell	-9,220	Closed	-$657K	–	1006
2019 Q2	$657K	Buy	9,220 +6,553	+246%	+$483K	﹤0.01%	670
2019 Q1	$209K	Sell	2,667 -1,403	-34%	-$106K	﹤0.01%	899
2018 Q4	$345K	Buy	4,070 +114	+3%	+$12.2K	﹤0.01%	752
2018 Q3	$677K	Sell	3,956 -212	-5%	-$32K	﹤0.01%	683
2018 Q2	$539K	Sell	4,168 -8	-0.2%	-$893	﹤0.01%	720
2018 Q1	$430K	Buy	4,176 +98	+2%	+$9.69K	﹤0.01%	786
2017 Q4	$348K	Buy	4,078 +205	+5%	+$17.8K	﹤0.01%	848
2017 Q3	$329K	Buy	3,873 +923	+31%	+$73.1K	﹤0.01%	895
2017 Q2	$223K	Sell	2,950 -684	-19%	-$47.8K	﹤0.01%	1026
2017 Q1	$240K	Buy	+3,634	New	+$239K	﹤0.01%	1037

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KeyBank National Association's LGND Position: Q2 2026 in Review

KeyBank National Association increased its Ligand Pharmaceuticals (LGND) stake by 9.3% in Q2 2026, buying an estimated $41.2K and bringing the position to 2,049 shares worth $648K. The position accounts for ﹤0.01% of the portfolio, ranked #803.

KeyBank National Association first reported a position in LGND in Q1 2017 and has held it in 14 quarters since. The position peaked at $677K in Q3 2018. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

KeyBank National Association held 2,049 shares of Ligand Pharmaceuticals worth $648K as of Q2 2026.
KeyBank National Association bought 175 Ligand Pharmaceuticals shares in Q2 2026, an estimated $41.2K.
Ligand Pharmaceuticals made up ﹤0.01% of KeyBank National Association's portfolio in Q2 2026, its #803 holding.
KeyBank National Association first reported a position in Ligand Pharmaceuticals in Q1 2017 and has held it in 14 quarters since.
KeyBank National Association's Ligand Pharmaceuticals position peaked at $677K in Q3 2018.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on KeyBank National Association's 13F filing for Q2 2026, filed 28 Jul 2026.